Oncogene cooperation in tumor maintenance and tumor recurrence in mouse mammary tumors induced by Myc and mutant Kras.
about
Seeding and propagation of untransformed mouse mammary cells in the lungIn silico discovery of small-molecule Ras inhibitors that display antitumor activity by blocking the Ras-effector interactionDiscovery of Small Molecules that Bind to K-Ras and Inhibit Sos-Mediated ActivationApproach for targeting Ras with small molecules that activate SOS-mediated nucleotide exchangeA method for the second-site screening of K-Ras in the presence of a covalently attached first-site ligandPrognostic and predictive significance of MYC and KRAS alterations in breast cancer from women treated with neoadjuvant chemotherapy.Regulation of transgenes in three-dimensional cultures of primary mouse mammary cells demonstrates oncogene dependence and identifies cells that survive deinduction.Tumour cell heterogeneity maintained by cooperating subclones in Wnt-driven mammary cancersKRAS and YAP1 converge to regulate EMT and tumor survivalThe Ras oncogene signals centrosome amplification in mammary epithelial cells through cyclin D1/Cdk4 and Nek2Metastatic pancreatic cancer is dependent on oncogenic Kras in miceTargeting mutant KRAS for anticancer therapeutics: a review of novel small molecule modulators.Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by Oncogenomic screeningOncogenic Ras/Src cooperativity in pancreatic neoplasia.KRAS Mouse Models: Modeling Cancer Harboring KRAS Mutations.The Rho GTPase Rnd1 suppresses mammary tumorigenesis and EMT by restraining Ras-MAPK signalling.Lymphomas that recur after MYC suppression continue to exhibit oncogene addiction.Linking tumor mutations to drug responses via a quantitative chemical-genetic interaction map.Role of JNK in mammary gland development and breast cancer.Molecular damage in cancer: an argument for mTOR-driven agingFinding cancer's weakest link.NCI's provocative questions on cancer: some answers to ignite discussion.Evidence that synthetic lethality underlies the mutual exclusivity of oncogenic KRAS and EGFR mutations in lung adenocarcinoma.Targeting synthetic lethal interactions between Myc and the eIF4F complex impedes tumorigenesisHeterogeneity in MYC-induced mammary tumors contributes to escape from oncogene dependenceCervical cancers require the continuous expression of the human papillomavirus type 16 E7 oncoprotein even in the presence of the viral E6 oncoproteinLead identification for the K-Ras protein: virtual screening and combinatorial fragment-based approacheseIF4F suppression in breast cancer affects maintenance and progressionNegative Selection and Chromosome Instability Induced by Mad2 Overexpression Delay Breast Cancer but Facilitate Oncogene-Independent Outgrowth.How genetically engineered mouse tumor models provide insights into human cancersDevelopment of mammary tumors by conditional expression of GLI1Transient regulatory T cell ablation deters oncogene-driven breast cancer and enhances radiotherapy.Genetic heterogeneity of Myc-induced mammary tumors reflecting diverse phenotypes including metastatic potential.Mutational landscape of EGFR-, MYC-, and Kras-driven genetically engineered mouse models of lung adenocarcinoma.Mouse tissues that undergo neoplastic progression after K-Ras activation are distinguished by nuclear translocation of phospho-Erk1/2 and robust tumor suppressor responses.Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets.Cooperative genomic alteration network reveals molecular classification across 12 major cancer types.A mouse model of MYCN-driven retinoblastoma reveals MYCN-independent tumor reemergence.Inducible and coupled expression of the polyomavirus middle T antigen and Cre recombinase in transgenic mice: an in vivo model for synthetic viability in mammary tumour progression.Cancer cell dormancy in novel mouse models for reversible pancreatic cancer: a lingering challenge in the development of targeted therapies.
P2860
Q24648060-4D8F6109-F8A4-413A-AC93-E05847B1574EQ27677868-DA4CF1AC-9479-4D58-BA34-D19FB97968C8Q27678948-28C6F1A0-FA43-47C8-A357-EEBF1B0B7B39Q27681830-65D772A9-10FF-44A6-BAC8-D8320C8F6DE7Q27684920-B1271B88-8C75-48D6-8FE4-98F12853ECF8Q31114634-66C8092C-32E5-4CC0-8E87-0D7B45A7A808Q33482643-F2E47045-1FAA-4A12-B4C7-4AA3EDC9BC74Q33731292-3A1187BD-250C-4587-8A73-9C3E28CB5C3BQ33946244-9FAA517C-E93A-405A-BF59-FF932164418EQ34273280-6B4FDFB9-3184-43C2-9F5D-8EC5A0396FEAQ34506422-23F3D1BF-D5BD-4740-9FC0-20EFDC0A22A6Q34659415-BDB3DB5F-B593-48A2-B409-03E4034D44D2Q34701235-E9A43DB0-AF56-420F-A1A8-27B6EC5AB712Q35015392-FA5BCC56-8648-4B7E-ADA8-72557CCF68CAQ35083740-70285F12-00E3-4989-9E5D-E46ECB127D39Q35218537-94A7B31E-4235-413F-81A3-5E4E1214B306Q35409292-EA49CE8E-95FF-47CC-B240-A80CA182FD24Q35531740-28FB6515-AC55-480A-A952-BE87890CBE8BQ35681017-FEB9C43F-F2DE-4582-8ECF-DDE2C0CDAE53Q35740772-3B3B9642-5279-473C-A059-47FDEF5155A8Q35764388-49CAB32A-93E6-4E09-A9FD-93608AD1D39EQ35764401-2BFE6DB5-9A4D-4C00-9AA6-9CB3CF5EB613Q35774120-0DE5A837-775C-4D2B-AA38-F30151C6A383Q35941539-FB04DB0B-BD0B-48D5-BCFB-9D5451A3EE35Q35973988-F8EE1227-DD4E-4FC7-8527-B0405E11C523Q36170110-DF2D4FB3-F81F-4349-A6EC-344CE9700656Q36883272-BEF05269-F5C7-4DC5-A48F-893F3613553FQ36892399-5B28B0D8-9C8C-4AAC-B0EE-9331C891AD45Q37037781-F245FF11-9EFB-456A-A9FB-5592509325F3Q37065678-73301C37-0486-4575-87C4-1EF9765C254FQ37211187-916D6A15-6D3A-4BC0-BBE6-6A32B3E7C3A9Q37246484-98163956-B116-403E-8C81-91B7C0679B2FQ37364112-35BEA6D2-EFBB-413A-976E-BB87CDDF7CD5Q37369422-CA45309D-B4CC-40DF-A998-01BCF3F92E3AQ37595370-2CB41B0F-E97E-4FFE-8F14-4253EFD936B0Q37624234-59CCB12D-B6D1-4C0E-9927-02735FF44625Q37649442-F39899F1-1626-4274-9E1F-814FA09DD990Q37672145-EE8F2805-7D07-4951-9477-94EB96BF888FQ37690882-F5F3443C-26AC-441D-97AA-84E206CA4CC3Q37712209-2D8FAC17-D91E-44D6-A033-3654EFBE92B4
P2860
Oncogene cooperation in tumor maintenance and tumor recurrence in mouse mammary tumors induced by Myc and mutant Kras.
description
2008 nî lūn-bûn
@nan
2008 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի մարտին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Oncogene cooperation in tumor ...... nduced by Myc and mutant Kras.
@ast
Oncogene cooperation in tumor ...... nduced by Myc and mutant Kras.
@en
Oncogene cooperation in tumor ...... nduced by Myc and mutant Kras.
@nl
type
label
Oncogene cooperation in tumor ...... nduced by Myc and mutant Kras.
@ast
Oncogene cooperation in tumor ...... nduced by Myc and mutant Kras.
@en
Oncogene cooperation in tumor ...... nduced by Myc and mutant Kras.
@nl
prefLabel
Oncogene cooperation in tumor ...... nduced by Myc and mutant Kras.
@ast
Oncogene cooperation in tumor ...... nduced by Myc and mutant Kras.
@en
Oncogene cooperation in tumor ...... nduced by Myc and mutant Kras.
@nl
P2860
P356
P1476
Oncogene cooperation in tumor ...... nduced by Myc and mutant Kras.
@en
P2093
Katrina Podsypanina
Levi J Beverly
P2860
P304
P356
10.1073/PNAS.0801197105
P407
P577
2008-03-20T00:00:00Z